Production (Stage)
Hepion Pharmaceuticals, Inc.
HEPA
$0.0722
$0.009214.60%
OTC PK
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | -30.90% | -22.03% | -25.92% | -25.72% | -18.20% |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | -58.52% | -57.25% | -46.95% | -30.79% | -24.90% |
Operating Income | 58.52% | 57.25% | 46.95% | 30.79% | 24.90% |
Income Before Tax | 60.75% | 67.24% | 45.16% | 30.36% | 18.51% |
Income Tax Expenses | 100.00% | -625.99% | -17.15% | -17.15% | -17.15% |
Earnings from Continuing Operations | 57.31% | 73.04% | 49.18% | 33.57% | 20.63% |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | 57.31% | 73.04% | 49.18% | 33.57% | 20.63% |
EBIT | 58.52% | 57.25% | 46.95% | 30.79% | 24.90% |
EBITDA | 58.45% | 57.26% | 46.96% | 30.81% | 24.95% |
EPS Basic | 82.45% | 82.39% | 64.25% | 45.95% | 29.96% |
Normalized Basic EPS | 73.29% | 64.64% | 57.17% | 38.07% | 25.83% |
EPS Diluted | 82.45% | 82.39% | 64.25% | 45.95% | 29.96% |
Normalized Diluted EPS | 73.29% | 64.64% | 57.17% | 38.07% | 25.83% |
Average Basic Shares Outstanding | 840.92% | 54.66% | 43.93% | 25.34% | 12.50% |
Average Diluted Shares Outstanding | 840.92% | 54.66% | 43.93% | 25.34% | 12.50% |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |